Literature DB >> 21651950

Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues.

Paul S Price1, Karl D Schnelle, Cheryl B Cleveland, Michael J Bartels, Paul M Hinderliter, Charles Timchalk, Torka S Poet.   

Abstract

The paper presents a case study of the application of a "source-to-outcome" model for the evaluation of the health outcomes from dietary exposures to an insecticide, chlorpyrifos, in populations of adults (age 30) and children (age 3). The model is based on publically-available software programs that characterize the longitudinal dietary exposure and anthropometry of exposed individuals. These predictions are applied to a validated PBPK/PD model to estimate interindividual and longitudinal variation in brain and RBC AChE inhibition (key events) and chlorpyrifos concentrations in blood and TCPy in urine (biomarkers of exposure). The predicted levels of chlorpyrifos and TCPy are compared to published measurements of the biomarkers. Predictions of RBC AChE are compared to levels of inhibition associated with reported exposure-related effects in humans to determine the potential for the occurrence of adverse cholinergic effects. The predicted distributions of chlorpyrifos in blood and TCPy in urine were found to be reasonably consistent with published values, supporting the predictive value of the exposure and PBPK portions of the source-to-outcome model. Key sources of uncertainty in predictions of dietary exposures were investigated and found to have a modest impact on the model predictions. Future versions of this source-to-outcome model can be developed that consider advances in our understanding of metabolism, to extend the approach to other age groups (infants), and address intakes from other routes of exposure.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651950     DOI: 10.1016/j.yrtph.2011.05.009

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  4 in total

1.  The need for non- or minimally-invasive biomonitoring strategies and the development of pharmacokinetic/pharmacodynamic models for quantification.

Authors:  Charles Timchalk; Thomas J Weber; Jordan N Smith
Journal:  Curr Opin Toxicol       Date:  2017-06

2.  Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction.

Authors:  Jingtao Lu; Michael-Rock Goldsmith; Christopher M Grulke; Daniel T Chang; Raina D Brooks; Jeremy A Leonard; Martin B Phillips; Ethan D Hypes; Matthew J Fair; Rogelio Tornero-Velez; Jeffre Johnson; Curtis C Dary; Yu-Mei Tan
Journal:  PLoS Comput Biol       Date:  2016-02-12       Impact factor: 4.475

Review 3.  Advancing human health risk assessment: integrating recent advisory committee recommendations.

Authors:  Michael Dourson; Richard A Becker; Lynne T Haber; Lynn H Pottenger; Tiffany Bredfeldt; Penelope A Fenner-Crisp
Journal:  Crit Rev Toxicol       Date:  2013-07       Impact factor: 5.635

4.  Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation.

Authors:  Miyoung Yoon; Harvey J Clewell
Journal:  Toxicol Res       Date:  2016-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.